<DOC>
	<DOCNO>NCT01445899</DOCNO>
	<brief_summary>This two-part study . The first part ( Stratum I ) open-label , dose escalation , safety , tolerability pharmacokinetic study , active study drug ( PF-04523655 ) give patient participate . Stratum I determine maximum tolerated dose dose-limiting toxicity . The second part ( Stratum II ) prospectively randomize , multi-center , double-masked , dose range study evaluate efficacy safety PF-04523655 alone combination ranibizumab versus ranibizumab alone patient DME .</brief_summary>
	<brief_title>PF-04523655 Dose Escalation Study , Evaluation PF-04523655 With/Without Ranibizumab Diabetic Macular Edema ( DME )</brief_title>
	<detailed_description>Patients enrol concurrently accord one two set criterion designate Stratum I Stratum II . 1 . Stratum I enroll 24 subject low vision , inclusive possible intermediate dos , 4 cohort 3-6 evaluable subject . 2 . Stratum II enroll approximately 240 subject DME 1:1:1:1 4 cohort 60 evaluable subject .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Key Stratum I 1 . Visual acuity study eye ≤ 20/200 . 2 . Low visual acuity result irreversible condition affect posterior segment study eye . Key Stratum I 1 . History vitrectomy . 2 . History IVT injection study eye within last 6 month . 3 . History vitreous hemorrhage , retinal detachment , invasive trauma study eye . 4 . History uveitis endophthalmitis either eye . 5 . Any active inflammatory condition study eye . 6 . Received drug know cause optic nerve retinal toxicity within 14 day prior dose . 7 . Any medical condition , concomitant therapy previous incisional laser surgery , opinion Investigator , would preclude IVT injection study eye . 8 . Intraocular pressure either eye ≥25 mmHg maximal medication . 9 . Cataract surgery laser corneal surgery within 3 month prior dose study eye intraocular surgery time . 10 . Participation concurrent interventional study within 30 day prior dose . Key Stratum II 1 . History diabetes mellitus ( Type 1 Type 2 ) . 2 . Retinal thicken secondary edema cause diabetes mellitus . 3 . Best correct visual acuity ( BCVA ) 20/40 bad 20/320 good study eye Screening . 4 . Standard care treatment DME withhold least 90 day subject enrol study ( study eye ) . Key Stratum II 1 . History panretinal photocoagulation within 6 month macular laser photocoagulation within 3 month prior dose study eye . 2 . Any IVT injection therapy perform study eye within 3 month prior dose . 3 . Iris neovascularization , vitreous hemorrhage , tractional retinal detachment , vitreomacular traction , clinically significant epiretinal membrane clinically significant preretinal fibrosis involve macula study eye . 4 . History vitreoretinal surgery incisional glaucoma surgery study eye . 5 . Prior intraocular surgery corneal laser surgery , perform within 3 month prior dose study eye . 6 . Received drug know cause optic nerve retinal toxicity within 14 day prior dose . 7 . High risk ( opinion Investigator ) proliferative diabetic retinopathy ( PDR ) study eye . 8 . Current infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye . 9 . Monocular subject . 10 . History idiopathic autoimmune uveitis either eye . 11 . Aphakia absence posterior capsule study eye . 12 . Structural damage center macula study eye likely preclude improvement visual acuity follow resolution macular edema . 13 . Uncontrolled glaucoma either eye . 14 . Spherical equivalent refractive error study eye 8 diopter myopia . 15 . Use corticosteroid , Investigator 's opinion , may change status subject 's diabetic retinopathy study eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>